Terapia inmunomoduladora sistémica en el tratamiento de la dermatitis atópica: el valor de Tralokinumab
Systemic immunomodulatory therapy in the management of atopic dermatitis: the value of Tralokinumab
DOI:
https://doi.org/10.25176/RFMH.v23i3.5593Palabras clave:
Dermatitis Atópica, Tralokinumab, Inmunomodulación, Interleucina-13, Terapia de InmunomodulaciónResumen
N/A
Descargas
Citas
Kelly KA, Perche PO, Feldman SR. Therapeutic Potential of Tralokinumab in the Treatment of Atopic Dermatitis: A Review on the Emerging Clinical Data. Clin Cosmet Investig Dermatol. 2022; 15:1037-1043. DOI: 10.2147/CCID.S267217
Singh R, Taylor A, Shah MA, Strowd LC, Feldman SR. Review of Tralokinumab in the Treatment of Atopic Dermatitis. Ann Pharmacother. 2023; 57(3):333-340. DOI: 10.1177/10600280221105686
Drucker AM, Morra DE, Prieto-Merino D, Ellis AG, Yiu ZZN, Rochwerg B, et al. Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis. JAMA Dermatol. 2022; 158(5):523-532. DOI: 10.1001/jamadermatol.2022.0455
Institute of Medicine (US) Committee on the US Commitment to Global Health. The US Commitment to Global Health: Recommendations for the Public and Private Sectors. Washington (DC): National Academies Press (US); 2009. Summary. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK23788/
Silverberg JI, Toth D, Bieber T, Alexis AF, Elewski BE, Pink AE, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021; 184(3):450-463. DOI: 10.1111/bjd.19573
Gutermuth J, Pink AE, Worm M, Soldbro L, Bjerregård Øland C, Weidinger S. Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7). Br J Dermatol. 2022; 186(3):440-452. DOI: 10.1111/bjd.20832
Soehoel A, Larsen MS, Timmermann S. Population Pharmacokinetics of Tralokinumab in Adult Subjects With Moderate to Severe Atopic Dermatitis. Clin Pharmacol Drug Dev. 2022; 11(8):910-921. DOI: 10.1002/cpdd.1113
Lai B, Phan K, Lewis N, Shumack S. A rare case of vernal keratoconjunctivitis in a patient with atopic dermatitis treated with tralokinumab. J Eur Acad Dermatol Venereol. 2022; 36(5):e343-e345. DOI: 10.1111/jdv.17824
Wang B, Goodman J, Roskos LK. Mechanistic modeling of a human IgG4 monoclonal antibody (tralokinumab) Fab-arm exchange with endogenous IgG4 in healthy volunteers. CPT Pharmacometrics Syst Pharmacol. 2022; 11(4):438-446. DOI: 10.1002/psp4.12738
Lozada-Martinez ID, Suarez-Causado A, Solana-Tinoco JB. Ethnicity, genetic variants, risk factors and cholelithiasis: The need for eco-epidemiological studies and genomic analysis in Latin American surgery. Int J Surg. 2022; 99:106589. DOI: 10.1016/j.ijsu.2022.106589
Adikusuma W, Irham LM, Chou WH, Wong HS, Mugiyanto E, Ting J, et al. Drug Repurposing for Atopic Dermatitis by Integration of Gene Networking and Genomic Information. Front Immunol. 2021; 12:724277. DOI: 10.3389/fimmu.2021.724277
Pérez-Fontalvo NM, De Arco-Aragón MA, Jimenez-García JDC, Lozada-Martinez ID. Molecular and computational research in low- and middle-income countries: Development is close at hand. J Taibah Univ Med Sci. 2021; 16(6):948-949. DOI: 10.1016/j.jtumed.2021.06.010
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2023 Revista de la Facultad de Medicina Humana
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
